Rett syndrome (RTT) is a rare genetic neurological disorder that primarily affects girls and causes severe impairments in nearly every aspect of the child’s life, including their ability to speak, walk, eat, and even breathe easily. Rett syndrome is usually recognized in children aged 6 to 18 months when they begin to miss developmental milestones or lose previously acquired abilities. RTT is caused by mutations on the X chromosome on a gene called MECP2. The early-onset seizure type (Hanefeld variant) is frequently caused by mutations in the X-linked CDKL5 gene (Xp22). A translocation involving the NTNG1 gene (1p13.2-p13.1) has also been identified in a patient with early seizures and atypical RTT. The congenital variant (Rolando variant) is generally caused by mutations in the FOXG1 gene (14q11-q13).
- The prevalence of Rett syndrome varies worldwide; in the USA, the estimated prevalence is 0.45 to 0.76 cases per 10,000 females aged 2 to 18 years. Germany is the leading and followed by France in the EU region in terms of total diagnosed and prevalent cases.
Thelansis’s “Rett Syndrome (RTT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Rett Syndrome (RTT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Rett Syndrome (RTT) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Rett Syndrome (RTT) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Thelansis 